Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDL-AP7 is a first generation phosphono NMDA antagonist. Anticonvulsant.
分子量 | 225.18 |
公式 | C7H16NO5P |
储存 | Store at RT |
CAS Number | 85797-13-3 |
PubChem ID | 3122 |
InChI Key | MYDMWESTDPJANS-UHFFFAOYSA-N |
Smiles | NC(C(O)=O)CCCCCP(O)(O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024
Meldrum and Chapman (1994) Competitive NMDA antagonists as drugs. In The NMDA Receptor (2nd edition). Eds. G. L. Col 457
关键词: DL-AP7, DL-AP7 supplier, Selective, Specific, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlu, Ionotropic, 78966-69-5, 0104, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 DL-AP7 的部分引用包括:
Stevens et al (2010) Light-evoked NMDA receptor-mediated currents are reduced by blocking D-serine synthesis in the salamander retina. Neuroreport 21 239 PMID: 20101193
Gustafson et al (2007) Endogenous D-serine contributes to NMDA-receptor-mediated light-evoked responses in the vertebrate retina. J Neurophysiol 98 122 PMID: 17507508
目前没有该产品的评论。 Be the first to review DL-AP7 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.